Harada, Makoto
Adam, Jonathan
Covic, Marcela
Ge, Jianhong
Brandmaier, Stefan
Muschet, Caroline
Huang, Jialing
Han, Siyu
Rommel, Martina
Rotter, Markus
Heier, Margit
Mohney, Robert P.
Krumsiek, Jan
Kastenmüller, Gabi
Rathmann, Wolfgang
Zou, Zhongmei
Zukunft, Sven
Scheerer, Markus F.
Neschen, Susanne
Adamski, Jerzy
Gieger, Christian
Peters, Annette
Ankerst, Donna P.
Meitinger, Thomas
Alderete, Tanya L.
de Angelis, Martin Hrabe
Suhre, Karsten
Wang-Sattler, Rui
Funding for this research was provided by:
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Article History
Received: 5 February 2024
Accepted: 28 May 2024
First Online: 12 June 2024
Declarations
:
: All animal studies were conducted in accordance with FELASA protocols and approved by the District Government of Upper Bavaria, Germany (Regierung von Oberbayern, Gz.55.2 1 54 2531 70 07, 55.2 1 2532 153 11). KORA S4 and F4 studies were approved by the Ethics Committees of the Bavarian Medical Association in Munich, Germany. All protocols of the QBB study were approved by the Hamad Medical Corporation Ethics Committee. All study participants provided written informed consent.
: Not applicable.
: M.F.S. was employed at Helmholtz Munich during the execution of this study. He is currently an employee of the Global Medical Affairs and Pharmacovigilance Department of BAYER AG Pharmaceuticals (Berlin, Germany), however, the company was not involved in work related to data generation and manuscript generation. S.N. was employed by the Helmholtz Munich during the execution of this study. She is currently an employee of Sanofi Aventis Deutschland GmbH; however, the company was not involved in work related to data and manuscript generation.